MedeliX
Start asking

nerandomilast

Jascayd · ATC code L04AA61

Key facts
Active substance
nerandomilast
Drug class
Immunosuppressive drug
ATC code
L04AA61
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Jascayd 9 mg film-coated tablets / Jascayd 18 mg film-coated tablets
Marketing authorisation holder
Boehringer Ingelheim International GmbH
Information as of
2026-10-27

Key facts

Nerandomilast is an oral phosphodiesterase 4 inhibitor with preferential inhibition of PDE4B. It is used in adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

What it is used for

  • Idiopathic pulmonary fibrosis (IPF) in adults
  • Progressive pulmonary fibrosis (PPF) in adults

Dosing

  • Recommended: 18 mg twice daily, approximately 12 hours apart
  • For diarrhoea or weight decrease, may be reduced to 9 mg twice daily (not with pirfenidone or CYP3A inducers)
  • With strong CYP3A inhibitors: 9 mg twice daily
  • With pirfenidone or strong/moderate CYP3A inducers: 18 mg twice daily, no reduction
  • No adjustment in the elderly, renal impairment or mild to moderate hepatic impairment; not recommended in severe hepatic impairment
  • Do not take an extra dose for a missed one

Contraindications

  • Hypersensitivity to the active substance or any excipient

Important warnings

  • Diarrhoea, nausea and decreased appetite, especially with nintedanib or pirfenidone; manage symptomatically
  • Weight decrease
  • Suicidal ideation and behaviour have been reported in clinical studies

Side effects

  • Very common: diarrhoea
  • Common: decreased appetite, weight decreased
  • Nausea

Interactions

  • Metabolised mainly by CYP3A; P-gp substrate
  • Strong CYP3A inhibitors (e.g. clarithromycin, itraconazole, ritonavir) increase exposure – reduce dose
  • Strong or moderate CYP3A inducers (e.g. carbamazepine) and pirfenidone decrease exposure

Pregnancy and breastfeeding

  • No data in pregnant women; animal studies suggest possible loss of pregnancy
  • Not recommended during pregnancy or in women of childbearing potential not using contraception

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • JascaydBoehringer Ingelheim International GmbH · EMEA/H/C/006405

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Jascayd
Liechtenstein
Jascayd
Norway
Jascayd

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Jascayd – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/jascayd-epar-product-information_en.pdf
  2. Wikidata (CC0): ATC L04AA.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.